



















































Patient 13 , age 16; age specific target volume includes CSF only. Patient 10 , age 9; age specific target volume includes CSF and VB. 
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Background: As the number of proton therapy centers increases, so does the need for studies which compare
proton treatments between institutions and with photon therapy. However, results of such studies are highly
dependent on target volume definition and treatment planning techniques. Thus, standardized methods of
treatment planning are needed, particularly for proton treatment planning, in which special consideration is paid to
the depth and sharp distal fall-off of the proton distribution. This study presents and evaluates a standardized
method of proton treatment planning for craniospinal irradiation (CSI).
Methods: We applied our institution’s planning methodology for proton CSI, at the time of the study, to an
anatomically diverse population of 18 pediatric patients. We evaluated our dosimetric results for the population as a
whole and for the two subgroups having two different age-specific target volumes using the minimum, maximum,
and mean dose values in 10 organs (i.e., the spinal cord, brain, eyes, lenses, esophagus, lungs, kidneys, thyroid,
heart, and liver). We also report isodose distributions and dose-volume histograms (DVH) for 2 representative
patients. Additionally we report population-averaged DVHs for various organs.
Results: The planning methodology here describes various techniques used to achieve normal tissue sparing. In
particular, we found pronounced dose reductions in three radiosensitive organs (i.e., eyes, esophagus, and thyroid)
which were identified for optimization. Mean doses to the thyroid, eyes, and esophagus were 0.2%, 69% and 0.2%,
respectively, of the prescribed dose. In four organs not specifically identified for optimization (i.e., lungs, liver,
kidneys, and heart) we found that organs lateral to the treatment field (lungs and kidneys) received relatively low
mean doses (less than 8% of the prescribed dose), whereas the heart and liver, organs distal to the treatment field,
received less than 1% of the prescribed dose.
Conclusions: This study described and evaluated a standardized method for proton treatment planning for CSI.
Overall, the standardized planning methodology yielded consistently high quality treatment plans and perhaps
most importantly, it did so for an anatomically diverse patient population.
Keywords: Proton, Craniospinal irradiation, CSI, Medulloblastoma* Correspondence: rhowell@mdanderson.org
1Department of Radiation Physics, The University of Texas MD Anderson
Cancer Center, Houston, TX, USA
2The University of Texas Graduate School of Biomedical Sciences at Houston,
Houston, TX, USA
Full list of author information is available at the end of the article
© 2013 Giebeler et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Giebeler et al. Radiation Oncology 2013, 8:32 Page 2 of 16
http://www.ro-journal.com/content/8/1/32Background
The number of cancer centers that offer proton therapy
as a treatment option is rising. Within the last 10 years,
the number of proton centers worldwide has almost
doubled; from 22 in 2003 to 38 in 2012. The rate of in-
crease has been even more pronounced in the United
States: in 2003, there were 3 active centers in the U.S.,
and currently there are 10 active centers, with 6 more
scheduled to open within the next 2 years. As a result,
there is increased interest in comparing treatment effica-
cies and toxicities from proton therapy to those of
photon therapy [1-3]. This is especially true for children,
[4-6] for whom survival rates are high, making proton
therapy’s potential for sparing normal tissues particularly
relevant. Particular attention has been paid to craniosp-
inal irradiation (CSI) in pediatric patients [7-10] because:
(1) CSI is a standard component in the treatment for
medulloblastoma, the second most common solid tumor
in children [11-13]; (2) the potential to reduce dose an-
terior to the spine with proton CSI could lead to
reduced toxicity in organs such as the thyroid, heart,
and lungs [13,14]; and (3) still-developing normal tissues
in children are highly radiosensitive [15]. As a result,
treatments that irradiate large portions of the body, such
as CSI, are of particular concern.
Until recently, the limited number of proton centers in
operation has limited the amount of patient-outcomes
data available for review, especially for pediatric patients.
As a result, comparisons between proton and photon
treatments have typically been performed using indirect
comparisons using case studies or nonrandomized
groups [2,16]. Additionally, many previous studies have
been criticized for focusing on improvements in proton
therapy (i.e., comparing outcomes between different pro-
ton techniques) rather than comparisons between pro-
ton and photon therapies [1,3,16-19]. Thus, although the
existing studies provide valuable insight, there is a de-
finitive need for studies that rigorously compare the
risks and benefits of using proton and photon irradiation
in clinical settings. Because the results of such studies
are highly dependent on the target volume definition
and treatment planning techniques, standardized, i.e.,
documented and reproducible, methods of proton and
photon treatment planning are needed to reliably per-
form these comparisons across a population of patients.
Treatment planning for photon CSI is well understood
and thoroughly described in the literature [20-22]. Con-
versely, a comprehensive description of treatment plan-
ning for proton CSI does not exist in the literature.
The objective of this study was to describe and evalu-
ate a standardized method for proton treatment plan-
ning for CSI. We present a detailed methodological
description of the planning techniques used at our insti-
tution, at the time of this study, for proton CSI. Then,we describe application of this methodology to a sample
population of 18 pediatric patients. Finally, we compared
dosimetric properties of the treatment plans resulting
from the methodology to determine whether the meth-
odology yields consistently high quality plans.
Methods
Facility-specific technical information
To better enable comparison between the treatment
techniques described here and those used by other insti-
tutions, we briefly review the technical features our
treatment system, i.e., The University of Texas M.D.
Anderson Cancer Center Proton Therapy Center Houston
(MDACC-PTCH), that are of relevance to passively scat-
tered proton CSI. The proton treatment system (Probeat,
Hitachi America Limited, Inc, Tarrytown, USA) consists of
a synchrotron (70–250 MeV) and a beam transport system
that bifurcates into six treatment stations. The CSI treat-
ments described in this work were planned for rotating
gantries with passive-scattering nozzles; we have two such
gantries at our institution, allowing patients to be easily
switched between treatment rooms. Specifically the nozzle
includes a rotating range modulator wheel, a binary stack
of range shifters, a contoured and compensated double
scattering system, beam monitoring instrumentation, colli-
mators, and a range compensator. This treatment equip-
ment can produce beam energies (defined at the nozzle
entrance) of 100, 120, 140, 160, 180, 200, 225, and
250 MeV, spread-out-Bragg-peaks ranging in size from
2 to 16 g/cm2, and field sizes of up to 25 x 25 cm2. The
dose rate depends on the scatterer (small, medium, or
large) that is in place. CSI fields are commonly treated
with a large scatterer and have a dose rate of approxi-
mately 1 Gray (Gy) min per minute at isocenter. The lay-
out, capabilities, and performance characteristics of the
treatment equipment were previously described in detail
in the literature [23,24].
The various modes proton beam operation (treatment,
physics, and service) is managed by an overall control
system. In addition, there is an independent safety con-
trol system. Data management is handled by the oncol-
ogy information system (MOSAIQ, IMPAC Medical
Systems Inc Sunnyvale, CA) [24]. For proton treatment
planning, we use a commercial treatment planning sys-
tem (TPS) (Eclipse version 8.9, Varian Medical Systems,
Palo Alto, CA). Dose calculations are performed with a
proton pencil beam algorithm [25] on a 2.5-mm iso-
tropic dose calculation grid.
The patient treatment couch (in the treatment room
described above) is a computer controlled robotic sys-
tem with three orthogonal axes of translation (vertical,
longitudinal, and lateral) and three orthogonal rotational
axes (pitch, roll, and yaw). Because of the large size of
the gantry and its pit, the couch base is mounted outside
Giebeler et al. Radiation Oncology 2013, 8:32 Page 3 of 16
http://www.ro-journal.com/content/8/1/32of the gantry and the couch top is mounted to the couch
base in a cantilevered configuration. The couch top ex-
tension, the portion of the couch top in contact with the
patient, is predominantly made of a carbon fiber com-
posite material that was specially selected for its
strength, uniform transparency to the beams of kilovol-
tage photons used for radiographic patient positioning
and alignment, and uniform and minimal perturbation
of proton treatment beams.General plan overview
The beam arrangements for proton CSI include two
opposed lateral oblique cranial fields and postero-anterior
spinal field(s). For standard-risk medulloblastoma patients,
we prescribe 23.4 Gy (RBE [relative biological effective-
ness]) (i.e., 21.3 Gy × 1.1 RBE). The units of Gy (RBE) are
assigned in accordance with our clinic’s standard of care
and the recommendations of ICRU Report 78, [26] which
assumes proton beams have a higher RBE than photon
beams. The fractionation schedule is 1.8 Gy per fraction
for 13 fractions with 3 junction shifts. Typically, junction
shifts are 1–2 cm apart, depending on spine length. The
general clinical guidelines used for proton CSI included
the following: (1) coverage of the cerebrospinal fluid (CSF)
by the 100% isodose to lower end of the thecal sac (S2 or
S3); (2) good coverage of the anterior skull base; (3) as
much coverage as possible to the cribriform plate,
balanced with planning criteria that the 100% isodose does
not intercept the eyes; (4) maximum isodose line inter-
cepting the thyroid should be 5% or less (isodose lines
visually evaluated slice by slice); (5) no overshoot into the
esophagus; and (6) a homogeneous dose across the the
spinal cord without excessive hot or cold spots (> 105% of
the prescribed dose or < 95% of the prescribed dose).
Patient immobilization and imaging
The immobilization technique used at our institution for
proton CSI is described below; it has, in our experience,
led to reproducible set-ups. Patients undergo computer
tomography (CT) simulation in the supine position on a
(10 cm thick) polystyrene foam slab (Associated Foam
Plastics, Houston, USA) that is inserted between the pa-
tient and the table top. The foam slab is a rigid hard plate
and does not conform to the patient. This slab elevates the
patient so that oblique cranial fields do not pass through
the treatment couch. Additionally, the patient’s head is
immobilized with a thermoplastic mask (WFR/Aquaplast
Corp. and Qfix Systems, LLC, Avondale, USA) and plastic
head holder (Medtech, CIVCO, Orange City, USA) to
optimize the neck curvature for patient sedation needs
and cranial field placement. A photograph and a sagittal
CT image of the patient set-up and immobilization are
show in Figures 1 and 2, respectively.After the patients are immobilized, CT images are
acquired using a multi-slice CT scanner (General Electric
LightSpeed RT16, GE Healthcare, Waukesha, USA). CT
images are acquired with a 2.5-mm slice thickness in an
area that extends approximately 2–3 cm superior to
the patient’s thermoplastic mask holder to approximately
3–4 cm inferior to the patient's sacrum. Additionally, the
entire thickness of any object with potential to be in the
beam path is included in the scan. Intravenous contrast
agents are not used in CT imaging for CSI planning be-
cause currently available agents do not enhance our ability
to delineate the CSF target. In addition, use of such agents
would artificially increase the Hounsfield units (HU)
values, which could result in overshoot of the proton
beams, i.e., irradiation of tissue distal to the craniospinal
axis [27].
Image processing and contours
Before the CT scan is imported into the TPS, it is post
processed to delete the portion of the image containing
the CT couch top extension (the portion of the couch
that is in contact with the patient, Figure 2) and to insert
a digital representation of the extension in its place.
Inserting a treatment couch top that mimics the physical
dimensions and materials of the actual treatment couch
top is important because the accuracy of the delivered
proton beam range requires accurate knowledge of the
materials through which the beam passes during the
planning process. The digital couch used at our institu-
tion was described elsewhere [28] and a similar digital
couch was reported for treatment planning at the proton
facility in Korea [29].
Similar to conventional photon therapy, target volume
contours in proton therapy are used to define the lateral
shape of the treatment field (i.e., block definition). How-
ever, unlike their photon counterparts, contours for tar-
gets and critical structures in proton treatments are
used by the TPS to automatically select beam range in
the patient and the width of the spread-out Bragg peak
(SOBP) so that it covers the target in the direction of
the beam axis. To insure that the TPS correctly assigns
these machine parameters, the HU are manually reas-
signed for any contours that include high density objects
or imaging artifacts. Surgical clips or screws, and cathe-
ters are examples where HU are re-assigned for CSI
treatment planning; such manual corrections were
required for about one-third of the patients included in
this study. These manual heterogeneity corrections are
particularly important for spinal treatment fields that are
oriented in the posterior-anterior direction, with the
spinal target in the posterior aspect of the patient and
most normal tissues at risk are either anterior or lateral
to it. Heterogeneity correction methods for proton treat-
ment planning were described in detail elsewhere [30].
Figure 1 Photograph of a patient in the set-up position for proton CSI.
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the entire CSF space (including the brain, and spinal canal
through the cauda equina to the level of the S2/S3 verte-
bral junction [Figure 3b]). However, to account for some
of the age-specific considerations of designing spinal treat-
ment fields, we define the anterior edge of the target vol-
ume in the spine in two ways (Figures 3a, b). For patients
who have not reached skeletal maturity as determined by
bone age, (typically those younger than 15 years of age),
the target volume includes the spinal canal and an add-
itional normal tissue target volume (NTTV), which
includes the entire vertebral bodies. As we described in a
recent study [31], the rationale for this “is to avoid sharp
dose gradients in the vertebral bodies in patients whose
skeletons are still maturing. More specifically, proton
treatments that are designed to irradiate only the spinal
canal have high dose gradients distal to the spinal canal
and lead to non-uniform irradiation of the vertebral bod-
ies. Uniformly irradiating a larger target volume that fully
encompasses the vertebral bodies is thought to reduce the
risk of asymmetric growth of the vertebral body in patients
whose skeletons are still maturing, [7,32], i.e., those under
the age of 15 years.” For patients older than 15 years, the
spinal portion of the CTV includes only the spinal canal
and extends no more than 2–3 mm into the vertebral bod-
ies, reducing the dose to bone marrow which may allow
for better tolerance of the chemotherapy that is required.
Field-specific details
Cranial fields in pediatric proton CSI are initially defined
by a target volume that includes the brain contour and
portions of the upper spine contour. The cranial fields are
typically angled 15 degrees from the horizontal plane to
reduce dose to the lens and improve dosimetric coverage
of the cribiform plate. Collimators are generally not
rotated, and a sufficient air gap (approximately 12–15 cm)
is provided to avoid collisions of the nozzle and couch top.
When designing the cranial fields, the inferior field edgesare typically designed first. They extend to the patient’s
shoulders to allow for feathering of the cranial-spinal field
junctions, i.e., the edges of the cranial fields in the
remaining junction-shifted plans are approximately 1 cm
and 2 cm superior to the shoulders. The remaining field
edges are defined superiorly by adding approximately
2.5 cm to the superior aspect of the brain contour
(for flash), and laterally by extending the brain contour in-
feriorly to the shoulders with a 2.5 cm margin on the
patient’s neck and editing the anterior neck contour off
the oral pharynx and mandible as much as possible. Add-
itionally, the right and left cranial fields are individually
edited so that their respective field edges approximately
bisect the right and left ocular globes, do not include ei-
ther lens, and maintain as much coverage of the cribri-
form plate as possible.
The spinal fields are initially defined by the CTV and
margins that include allowances for uncertainties in the
depth and lateral directions. The number of spinal fields
varies on the basis of spine length. In all cases, the su-
perior border of the uppermost spinal field is matched
to the inferior border of the cranial fields. Then, depend-
ing on the length of the spine, a second spinal field is
matched to the inferior border of the upper spinal field,
and if needed, a third spinal field is matched to the infer-
ior border of the second spinal field. Lateral field edges
are defined using a 1-cm margin around the spinal target
volume. Typical field borders for a representative adoles-
cent patient are shown in Figure 4.
Cranial and spinal field isocenters are selected during
treatment planning and are defined to simplify patient
setup. The field isocenters for the cranial fields are
placed at the patients’ midline such that they are, at
minimum, 3 cm from the field edges, i.e., 3 cm from the
internal edges of the cranial blocks. The field isocenter
for each spinal field is located at the same x coordinate
(left-right axis) as the cranial fields. The isocenter’s y co-





























Figure 2 Sagittal CT image showing the patient set-up and
immobilization for representative patient (patient 10: male,
age 9). The window and level of the image was adjusted to
visualize the digitally inserted couch top extension (the portion of
the couch that is in contact with the patient), foam pad,
thermoplastic mask, and plastic head holder. Isocenters for the
cranial field(s), upper spine filed, and lower spine field are indicated
with blue × and labeled 1, 2, and 3 respectively.
a. b.
Figure 3 Age-specific target volumes for two patients. (a) Target
volume for a 4-year-old patient included the spinal canal and the
entire vertebral body, and (b) target volume for a 15-year-old
patient included only the spinal canal. Both volumes also included
the brain.
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in the polystyrene foam pad posterior to the patient such
that the couch height in the room is high enough to re-
duce collision issues. The z (superior-inferior axis) co-
ordinate differs for each spinal field and is placed
midway between each field’s superior and inferior bor-
ders. Typical field isocenters for a representative adoles-
cent patient are shown in Figures 2 and 4.
Uncertainty margins
Uncertainty margins are designed for each treatment
field to ensure coverage of age specific target volumes
(described in the following section). Uncertainty marginsare calculated for each treatment field using a method-
ology similar to that used in our previous studies [30,33]
and following the methods originally outlined by Moyers
and Miller [34] and Moyers et al. [35]. The distal uncer-
tainty margin (DM) is determined using.
DM ¼ 0:035 Cdð Þ þ 0:3 cm; ð1Þ
where 3.5% of Cd, the water-equivalent depth (cm) to
the distal edge of a field’s target contour, is used to ac-
count for uncertainties in the CT number and the con-
version of the electron densities to proton relative linear
stopping powers. The 0.3 cm is added to account for
range uncertainty due to variations in accelerator energy,
material thickness in the scattering system, and compen-
sator density.
The proximal uncertainty margin, PM, is determined
using
PM ¼ 0:035 Cp





Figure 4 Proton therapy cranial and spinal field borders for CSI (a
representative patient) representative patient) in the (a) cranial
field, (b) upper spinal field, (c) middle spinal field, and (d) lower
spinal field. Field isocenters are indicated with red circle.
Giebeler et al. Radiation Oncology 2013, 8:32 Page 6 of 16
http://www.ro-journal.com/content/8/1/32where Cp is the water-equivalent depth (cm) to the prox-
imal edge of the field’s target contour. The lateral uncer-
tainty margin, LM, is determined using
LM ¼ IM þ SM þ P ð3Þ
where IM represents the margin for internal motion (cm),
SM represents setup uncertainty (cm), and P represents
the 50%–90% penumbral width (cm). Thus, the value of
LM defines the lateral expansion of the field-specific aper-
tures beyond the cranial and spinal target volumes.
According to our standard of care, IM is taken to be 0 cm
and SM 0.3 cm. For the spinal fields, this typically results
in an LM value of 1 cm. LM is also considered for the cra-
nial fields, but it serves as a baseline on which flash is
added to the superior aspect of the treatment fields.
Although the uncertainty margins for the cranial and
spinal fields are determined using the same equations,
there are some differences in how the margins are imple-
mented. For the cranial fields, PM and DM values are ap-
plied as planning parameters. That is, the TPS selects the
beam range, modulation, and energy based on the require-
ment that the prescribed dose is delivered to the cranial
target and its margins. Conversely, because there is a one-
to-one correspondence between each spinal target and
spinal field, values of PM and DM are incorporated into
the spinal targets, which expands the target region prox-
imal and distal to the spinal canal. This approach stream-
lines the optimization process because it provides
visualization of the uncertainty margins relative to the
dose distribution. As a result, edits for optimization can
be made judiciously.
Once the uncertainty margins are determined, the follow-
ing equation based on the works of Moyers et al. [35] and
Urie et al. [36] is applied. This equation defines the amount
of expansion or smearing of the range compensator. The
equation effectively decreases the range compensator thick-
ness such that proton penetration depth in the patient is
increased in order to maintain distal coverage in the pres-
ence of radiological path length variations due to internal
anatomical motion; note that this correction is variable




IM þ SMð Þ2 þ Cd  0:03ð Þ2
q
; ð4Þ
where S is the amount of smear determined using the
quantities IM, SM, and 3% of the Cd. S is calculated for the
spinal fields only. Most cranial fields are not designed to
have range compensators because even in the case of
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does not match the curvature or thickness gradients of the
patients’ skulls. Note that our comment rereading not using
range compensators for most brain fields specifically refers
to the type of cranial fields which are intended to cover the
whole brain; range compensators are used when planning
boost fields (not discussed in this study) because the field is
specifically conformed to cover a particular gross target vol-
ume rather than the entire brain).
Optimization of dose distributions
After the initial fields are optimized and calculated, the
dose distributions are reviewed, and we begin the
process of field-specific optimization. That is, each field
is individually optimized to provide uniform coverage of
target volumes and meet constraints on dose to normal
tissues. Typically, optimization begins with the cranial
fields. Cranial field optimization is done in several steps.
First, the general shape of the 23.4 Gy (RBE) isodose line
is reviewed to ensure that it includes the cerebrospinal
fluid in the subarachnoid space. Ideally, this means that
the 23.4 Gy (RBE) isodose line extends minimally to the
interior edge of the skull and maximally 1–2 mm outside
the exterior edge of the skull. If needed, adjustments to
the general shape of the 23.4 Gy (RBE) isodose line are
made through changes to the proximal and distal mar-
gins of the cranial fields. Then, to improve dosimetric
homogeneity within the cranial target region, we edit the
plan’s dose normalization value by selecting an initial
normalization value to create uniform coverage of the
cranial target region by the 23.4 Gy (RBE) isodose line.
The normalization is finely adjusted to reduce the higher
dose values or hot spots (at least 24.6 Gy (RBE)) that
would result from scatter in immobilization devices and
variations in skull thickness. At this point, if they were
being used, range compensators would be manually edited
to attenuate dose to the cochlea and smoothed (further
smeared) to reduce their impact on dosimetric inhomogen-
eity in the brain. For plans prescribed to 23.4 Gy (RBE),
most compensators are removed to reduce the number of
hot and cold streaks (> 105% of the prescribed dose or
< 95% of the prescribed dose) in the cranial dose distribu-
tions. For plans prescribed to 36 Gy (RBE), use of range
compensators to reduce dose to the cochlea is evaluated on
a case-by-case basis.
Next, the spinal fields are optimized for uniform
coverage of the 23.4 Gy (RBE) isodose line relative to the
age-specific spinal target. This process begins with the
uppermost spinal field and ends with the lowest spinal
field and involves several steps. First, the general shape
of the 23.4 Gy (RBE) isodose line is assessed relative to
the age-specific spinal target. Ideally, the distal edge of
the 23.4 Gy (RBE) isodose line coincides with the distal
edge of the spinal target, and the proximal edge of the23.4 Gy (RBE) isodose line coincides with the proximal
edge of the spinal target or, maximally, just anterior to
the dorsal skin surface. If needed, the general shape of
the 23.4 Gy (RBE) isodose line is adjusted relative to the
spinal target by making small changes to the proximal
and distal margins of the spinal fields. Second, to im-
prove dosimetric uniformity within the spinal target re-
gion, the weight of the spinal field is adjusted relative to
the plan normalization value. In general, spinal field
weights can differ from their initial setting of 1.0 by ±0.5%
to ±5%, and in most cases, the largest weight is assigned
to the field incident upon the sacrum. Third, field-specific
range compensators are edited to reduce hot and cold
spots in the dose distribution. These edits differ slightly
for each field because of differences in anatomy. In the
upper spinal field, edits are made to reduce hot and cold
spots due to scatter from the head holder or changes in
the neck curvature (e.g., interfraction variation in neck
flexion). Additionally, compensator thickness is increased
in the thyroid region to block isodose lines that are greater
than 5% of the prescribed dose from crossing the medial
edge of the thyroid contour. In the spinal field incident to
the sacrum, edits are made to increase compensator thick-
ness on the basis of the patient’s sacral curvature. In all
cases, field-specific edits to the compensators are made
and then smoothed (i.e., applied a smoothing function to
remove any abrupt steps in compensator topography
which can occur when a compensator is manually edited)
to ensure that small shifts in the patient setup do not
compromise dosimetric coverage of the spinal canal.
After, the spinal fields are optimized for uniform dosi-
metric coverage of the age-specific spinal target, atten-
tion is focused on reducing dose inhomogeneities at the
field junctions. The junction region is defined as
the region where the edges of the cranial/spinal and
spinal/spinal fields align: 2–3 CT slices in the superior
direction and 2–3 CT slices in the inferior direction.
This region is 1.25-1.50 cm in length, is contained lat-
erally and distally within the spinal target and is shifted
on a weekly basis. In the junction region, hot spots are
defined by isodose lines greater than 108% of the pre-
scribed dose, and cold spots are defined by isodose lines
less than 95% of the prescribed dose. Hot spots and cold
spots are removed using three procedures: edits to the
apertures forming the field junction, fine edits to the
field weights, and edits to the abutting fields' compensa-
tors. Edits to the apertures are made so that the field
edges will be precisely aligned to one another. Once the
fields are precisely aligned, the field weights are finely
adjusted to balance coverage of the spinal canal with the
100% isodose line and reductions in the dose at the field
junctions. After the field weights are optimized, remaining
regions of isodose lines greater than 110% of the pre-
scribed dose may indicate fine adjustments to the field
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that, the field compensators are edited, if needed. These
edits are designed to reduce hot spots in the spinal canal
by removing steep gradients within the compensator and
shifting hot spots from the spinal canal to the vertebral
body.
Finally, to assess the combined effects of the optimization
processes, the display of cranial and spinal target volumes
are turned off, and the location of the 100% isodose line
relative to the interior border of the skull and spinal canal
is evaluated for each of the three junction-shifted plans. If
needed, final edits to the isodose coverage are made by scal-
ing the 100% isodose line in an individual plan, but because
this final edit scales the dose distribution for all treatment
fields in an individual plan, it is rarely used. Once all three
junction-shifted plans individually meet the planning cri-
teria, they are combined and re-evaluated as a summed
plan. Then, based on the dosimetric evaluation of the
summed plan, final edits to the individual junction-shifted
plans are performed, if needed, until the summed plan
meets all objectives and constraints.
Patient population
To evaluate the quality of our treatment planning meth-
odology, we applied the methodology to an anatomically
diverse and representative population of patients. Eight-
een pediatric patients (ages 2 to 16 years of age) were
selected using the consecutive sampling method [37].
The inclusion criteria were male and female patients be-
tween 2 and 18 years of age at the time of treatment
who received proton CSI between 2006 and 2009 at the
UTMDACC-PTCH. Patients who received photon ther-
apy or who were not simulated in the supine position
were excluded. The sample was fairly evenly distributed
in age and sex. The patients varied with respect to ana-
tomical stature, age, and the corresponding volumes of
their internal organs (Table 1). For each patient the same
planning process was employed.
Evaluation of planning methodology
For each patient the treatment plans were evaluated to
assure adherence with our clinical guidelines by review-
ing the isodose distributions (on each axial CT slice) and
dose volume histograms (DVH) for the ten organs of
interest (lungs, liver, heart, kidneys, spinal cord, brain,
eyes, lenses, esophagus, and thyroid). Two representative
patients (indices 10 and 13) were selected for presenta-
tion in the results section of this manuscript. Patient 10
(age 9) is representative of the younger patients planned
with the larger age-specific target volume that included
CSF and vertebral bodies. Patient 13 (age 16) is repre-
sentative of the older patients planned with the smaller
age specific target volume that included only CSF. Both
patients were of average stature and their organ volumeswere within the corresponding one standard deviation of
the mean organ volumes of the population.
After evaluation of individual patient isodose distribu-
tions and DVHs, we completed population-based dosimet-
ric and statistical analyses. First, average DVHs were
generated for ten organs of interest by calculating the
average values of D5% to D100% (in 5% increments) and
maximum dose (Dmax). Next, for the same ten organs,
average values for minimum dose (Dmin), Dmax, were cal-
culated separately for the entire population of patients and
for the two subgroups of patients planned with the two
different age-specific target volumes. Values of mean dose
(Dmean) were similarly calculated. Finally, to quantify the
variation in machine parameters between patients’ treat-
ment fields, we determined the minimum, maximum, and
median for the proton beam range, energy, and SOBP
width for our population’s cranial and spinal fields.Results
Machine parameters for treatment delivery
Machine-specific treatment parameters for all 18 proton
CSI treatment plans are summarized in Table 2. As
described in Methods, these values were automatically
determined by the TPS on the basis of the treatment-
specific target contours. The variation in the proton
beam range, energy, and SOBP width within this popula-
tion is largely attributed to the wide interval in patient
age and, thus, the wide interval in patient size. In gen-
eral, median values for range, energy, and SOBP width
were higher for the cranial fields than for the spinal
fields. This difference is attributed to the larger axial size
of the cranial target than of the spinal target.
Dosimetric results
The DVHs and isodose distributions for two patients
(patient 10 and 13) are shown in Figures 5 and 6, re-
spectively. These plans were was optimized to deliver
mean doses between 103% and 104% of the prescribed
dose to the spinal cord and brain while dose to the eyes,
esophagus, and thyroid were reduced. Organs such as
the lungs, kidneys, heart, and liver were not specifically
identified for dose reduction, but using the outlined
methodology, dose to these organs was minimized. The
data for these two patients was typical of our observa-
tions for the entire population of patients. That is that
good normal tissue sparing was achieved for all patients
but normal tissue sparing was better in the older
patients when compared to the younger patients.
Organ-specific, population-averaged DVHs (for the 18
patients) are shown in Figure 7 for ten organs. In Table 3,
population-averaged dose-volume results (Dmin, Dmax,
and Dmean) for ten organs are reported separately for the
entire patient population, and for the two subgroups of
Table 1 Patient demographics including volumes of organs of interest, for which each organ was contoured in its
entirety*
Index Sex Age Thyroid Lungs Liver Kidneys Heart Esophagus Eyes Lens Spinal Cord Brain
(y) (cm3) (cm3) (cm3) (cm3) (cm3) (cm3) (cm3) (cm3) (cm3) (cm3)
1€ F 2 1.9 320.8 372 63.5 139.5 1.2 16.2 0.3 41.4 1047
2 F 4 3.2 548.1 633.8 127 218.9 8.8 14.7 0.2 53.5 1336
3 F 6 3.3 1062 631.5 125.4 158.9 4.7 16.5 0.3 49.1 1456
4 F 8 4.5 1048 733.5 136.9 258.6 6.9 14.1 0.2 32.5 1402
5 F 9 3.8 1072 886.4 190.9 264 8.6 18.9 0.3 47.9 1318
6 M 3 1.5 457.9 595.9 137.8 96.6 5.5 12.3 0.1 19.5 1554
7 M 4 3.9 626.6 596 110 199.8 15.1 25.3 0.4 56.4 1380
8 M 6 4.1 814.8 847.4 160.8 214.5 5.3 16.6 0.2 83 1481
9 M 8 2.3 881.4 556.9 135.1 222.9 6.9 11.9 0.2 69.5 1471
10 M 9 5.4 1116 1066 117.4 276.9 7 10.8 0.2 48.4 1253
11 F 12 1.7 1479 646.4 169.4 243.1 8.7 12.8 0.2 26.9 1204
12 F 13 4.3 796.1 1429 198.1 227 13.6 14.9 0.1 32.5 1266
13* F 16 7.7 1850 1867 283.5 474.6 18.9 15.8 0.3 82.1 1279
14 M 12 11.7 1673 1354 287.2 434.2 15 14.2 0.1 111.1 1335
15*† M 13 12.6 2482 1498 342.5 417.4 18.6 16.5 0.2 42.3 1907
16 M 14 7.8 1247 1006 207.3 53.7 10.3 22.2 0.2 93.3 1533
17* M 15 10 2273 1816 356.6 493.1 18.3 15.2 0.1 110.9 1401
18* M 16 14.3 2308 1869 487.1 821.9 24 19.4 0.4 169.2 1542
Mean (cm3) 9.4 5.8 1225.3 1022.5 202.0 289.8 11.0 16.0 0.2 65.0 1397.8
SD (cm3) 4.5 3.9 636.5 479.9 105.6 176.3 6.0 3.5 0.1 36.7 177.3
* Indicates patients whose target volume included the CSF and the entire vertebral bodies. All other patients’ target volumes included only the CSF.
† Patient was 13 years of age at the time of treatment, but assumed to be at skeletal maturity for treatment planning.
€ Due poor contour resolution, volume estimates for the esophagus and thyroid of patient #1 were not optimal. However, sensitivity tests indicate that changes in
the volumes for these organs by as much as 300% did not affect the mean values for the population.
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target volumes. Overall, the standard deviations in the
organ doses were lower for the subgroups compared to
the population as a whole (Table 3). The brain and
spinal cord were part of the target volume and naturally
had high doses for all patients, with little difference in
Dmin, Dmax, and Dmean observed between the entire
population and subgroups. Additionally, our planning
technique produced similar results across the population
of patents considered, as evidenced by low standard
deviations in the Dmin, Dmax, and Dmean values (Table 3)
and the D5% through the D95% values (Figure 7) for the
brain and spinal cord. For the remaining eight tissues
considered, good normal tissue sparing was achieved for
all of the patients (Table 3, Figure 7). However, com-
pared to the brain and spinal cord, there was larger
standard deviation in doses. This standard deviation was
largely related the age specific target volumes and to the
proximity of the target volume to the organ. The eyes
and the lenses received higher doses than other organs.
They are close to the cranial fields, and even with
optimization, dose could not be entirely eliminated by
editing field-defining apertures because of the finitepenumbral width. Not surprisingly, the dose to the eyes
and brain were similar in all patients, including the
patients with different age-specific spinal target volumes
because the cranial component of the target volume was
the same in all patients. The kidneys and lungs are both
lateral to the spinal fields, and therefore dose in these
organs was dependent on the lateral margins assigned to
the spinal target volume, which varied with patient age
and size. In the kidneys and lungs, higher doses were
observed for the patients whose target volume included
CSF and vertebral bodies compared to those whose tar-
get volumes only included CSF. The thyroid, liver, heart,
and esophagus are located distal to the spinal fields, and
therefore dose in these organs was largely governed by
their proximity anteriorly to the target volume. This dis-
tance was smaller in those patients whose spinal target
volumes included the entire vertebral bodies, and thus,
doses to the thyroid, liver, heart, and esophagus were
higher for these patients compared to those whose target
volumes only included CSF. Of these organs, the heart,
which was the most anterior, had the lowest mean dose,
whereas the esophagus, which was the most proximal,
had the highest mean dose.
Table 2 Values for the minimum, maximum, median, and
standard deviation (SD) across the population (N = 18) for
beam range (cm), energy (MeV) and width of the
modulated range or spread out Bragg peak (SOBP) (cm)
Cranial fields Spinal fields
Upper Middle Lower
Range (cm) Min - Max 14.7-20.60 8.5-15.4 6.6-13.6 7.6-16
Median 17.0 10.9 12.3 11.1
SD 1.3 1.9 2.7 2.2
Energy (MeV) Min - Max 180-225 140-200 140-200 140-200
Median 200 160 180 160
SD 12 17 18 17
SOBP (cm) Min - Max 15-16 4-7 4-8 4-7
Median 16 5 5 6
SD 1 1 2 1
Energy values correspond to set energy steps of 140 MeV, 160 MeV, 180 MeV,
200 MeV, and 225 MeV. Abbreviation in this table: spread out Bragg
peak (SOBP).
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In this study, we presented a standardized methodology
for treatment planning for passively-scattered proton CSI.
To evaluate our planning methodology, we reviewed
individual treatment plans and organ-specific population-
averaged DVHs (for the 18 patients) to quantitatively
evaluate the consistency of plan quality across the popula-

































Figure 5 Dose volume histograms (DVH) for two representative patie
patient 10: male, age 9 and dashed lines are for patient 13: female, age 16.tissue doses related to age specific target volumes by
separately evaluating dosimetric parameters for the en-
tire population and the two target volume subgroups. We
found that our standardized treatment planning method
yielded plans that were dosimetrically of high quality (i.e.,
generally satisfied the dosimetric criteria in the Methods
section) and dosimetrically consistent across the popula-
tion of 18 patients. For all patients, good normal tissue
sparing was achieved, but was better in the older patients
whose target volumes only included CSF compared to the
younger patients whose target volumes included the CSF
and entire vertebral bodies.
In our evaluation of the planning technique, we focused
on comparing dosimetric information for the population
in ten organs: lungs, liver, heart, kidneys, spinal cord,
brain, eyes, lenses, esophagus, and thyroid. The spinal
cord, lenses, eyes, and thyroid were specifically identified
in the planning technique for optimization. Because the
spinal cord is located in the target volume, the goal of the
planning method was to create a homogeneous dose
across the spinal cord without hot or cold spots
(dose >105% or <95% of the prescribed dose, respectively).
Mean dose across the population of patients was
2519.8 cGy (RBE) (107.6%) with a 1% SD, indicating high
consistency in the planning technique coverage, but be-
cause the mean dose was greater than 5% above the pre-
scribed dose, the dosimetric analysis revealed a potential
trend toward plans with a higher overall normalization. In
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Figure 6 Dose distributions for two representative patients with different age specific target volumes. Panels on the left are for patient
13, female, age 16 and panels on right are for patient 10: male, age 9. (a,e) Dose distribution in the axial plan at the level of the eyes. (b,g) Dose
distribution in the axial plane, taken at the vertebral space between T8-T9 to show dose relative to the liver, heart, lungs, esophagus, and cord.
(c,h) Dose distribution in the axial plane, taken at the vertebral space between L1-L2 to show dose relative to the liver, kidneys, and cord. (d,e)
Dose distribution in the sagittal plane, taken at a poisiton lateral to the cord to include aspects of the thyroid and esophagus in the image. (i)
Isodose scale for images (a–h).
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patient-specific edits. In the case of the thyroid, SD was
high (141%), suggesting a potential need for improved
standardization of the optimization technique. However,
because the mean organ dose was relatively low (4.9 cGy
(RBE)), the high SD may be a reflection of large variations
of low dose. Moreover an alternative method for reducing
dose to the thyroid that maintains the prescribed dose to
the spinal cord is not known at this time.
One way that our proton CSI treatment technique could
potentially be improved is through modifications to our pa-
tient immobilization and set-up. While the immobilization
technique used at our institution for proton CSI achieves
reproducible set-ups, it also results in increased lateral pen-
umbra of the proton treatment fields. Specifically the 10 cm
thick foam slab that is used to prevent the cranial fields
from intercepting the treatment couch creates a gap be-
tween the patient and the treatment couch which results in
increased lateral penumbra. The use of the foam slab wasoriginally implemented several years ago when we used a
relatively dense table-top insert that was placed on the
treatment couch to facilitate indexing immobilization
devices (MedTec, Kalona, IA, USA). At the time the density
of the table-top insert was not a concern because we were
only treating prostate cancer using lateral fields that did not
intercept it. Later when faced with the first proton CSI case
at our institution, we were concerned about the obliquely
angled cranial fields traversing the high density indexed
table-top insert. Eventually, though minor modifications to
the couches top extension, we were able to index patients
directly to the couch top extension and the indexing table
top insert was abandoned. Subsequently, we abandoned the
use of compensators for the cranial fields. With the removal
of the indexing table-top insert, the removal of the com-
pensator, and the low density nature of the t couch top
extensions, it is possible that elevating of the patients with
the 10 cm thick foam slab is no longer required. Reducing



























































































































































































































































































































































Figure 7 Average dose volume histogram (DVH) for the 18 patients in this study. Plots were generated by calculating the mean values of
D5% toD100% (in 5% increments) and Dmax for each organ contour. The error bars indicate one standard deviation of the mean. (a) thyroid, (b)
lungs, (c) liver, (d) kidneys, (e) heart, (f) esophagus, (g) eyes, (h) lenses, (i) spinal cord, and (j) brain.
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Table 3 The minimum, maximum, and mean dose values for the population (N = 18) in specific organs of interest are
listed along with the corresponding standard deviations (SD)
Dose SD SD/Dose Dose SD SD/Dose Dose SD SD/Dose
[cGy (RBE)] (%) [cGy (RBE)] (%) [cGy (RBE)] (%)
N 18 4 14
Target Volume All CSF space CSF space and VB
Spinal Cord Min 2225.3 92.3 4 2204.5 138.3 6 2231.3 73.1 3
Max 2576.2 52.9 2 2633.5 51.3 2 2559.9 40.5 2
Mean 2422.3 21.8 1 2436.6 11.5 0 2418.3 22.4 1
Brain Min 2070.7 190.2 9 2182.9 145.3 7 2038.7 189.4 9
Max 2590.3 85.9 3 2649.5 128.6 5 2573.4 59.1 2
Mean 2419.0 25.9 1 2410.8 10.1 0 2421.3 28.5 1
Eyes Min 379.7 302.2 80 310.0 210.8 68 399.7 320.8 80
Max 2404.9 65.1 3 2439.0 113.3 5 2395.1 36.8 2
Mean 1623.0 256.9 16 1533.3 186.1 12 1648.7 268.1 16
Lenses Min 713.5 382.7 54 640.6 406.6 63 734.3 373.6 51
Max 1602.1 241.5 15 1622.9 177.1 11 1596.1 256.6 16
Mean 1125.9 312.4 28 1085.9 311.3 29 1137.3 311.8 27
Kidneys Min 0.0 0.0 - 0.0 0.0 0.0 0.0 -
Max 2153.5 318.1 15 1773.1 445.2 25 2262.2 142.3 6
Mean 151.7 107.8 71 22.9 9.6 42 188.5 93.9 50
Lungs Min 0.0 0.0 - 0.0 0.0 - 0.0 0.0 -
Max 2446.3 103.4 4 2318.2 119.0 5 2483.0 60.6 2
Mean 175.9 89.8 51 74.8 17.9 24 204.8 80.7 39
Thyroid Min 0.0 0.0 - 0.0 0.0 - 0.0 0.0
Max 244.1 344.1 141 72.7 88.9 122 293.1 373.0 127
Mean 4.9 10.2 208 0.4 0.5 125 6.2 11.2 181
Liver Min 0.0 0.0 - 0.0 0.0 - 0.0 0.0 -
Max 2078.0 456.5 22 1435.0 408.4 28 2261.5 262.1 12
Mean 16.2 11.1 69 2.7 1.9 70 20.1 9.4 47
Heart Min 0.0 0.0 - 0.0 0.0 - 0.0 0.0 -
Max 1470.0 803.6 55 127.1 126.9 100 1853.7 404.0 22
Mean 18.2 17.0 93 0.2 0.1 50 23.3 15.9 68
Esophagus Min 0.1 0.4 - 0.0 0.0 - 0.2 0.4 -
Max 1825.8 864.1 47 300.0 171.0 57 2261.8 31.1 1
Mean 371.8 338.9 91 3.3 2.4 73 477.1 312.7 66
Also listed is the ratio of each SD to its respective dose value. Each organ was contoured in its entirety. In addition these data are presented separately for age
specific target volumes, i.e., CSF space (including index 13, 15, 17, and 18) or CSF space and vertebral bodies (VB) (all remaining indices).
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be particularly advantageous for reducing dose to the eyes
and lenses. However, moving forward, we will need to care-
fully consider changes to patient set-up and immobilization
prior to implementing any changes. Nonetheless, our ex-
perience may be useful for other institutions as they select
their treatment couches and immobilization devices; table
tops should be low density and allow immobilization
devices to be easily indexed. Also, gaps between thetreatment couch and patient should be minimized where
possible.
While there is a great need for studies which compare
proton treatments between institutions and with photon
therapy, to date there are only a few reports in the litera-
ture that compare photon CSI and passively scattered
proton CSI. Furthermore, it is difficult to fully interpret
the results of these studies because none have provided
a detailed description of the proton planning techniques
Table 4 Planning parameters specified in current treatment planning studies for passively scattered proton CSI
Planning Parameters Proton Planning Studies in the Literature
Yuh et al.
[10]








Number of Patients 3 1 10 1 2
Patient Age (y) 3 − 4 3.6 2 − 17 3 9,10
Cranial Field Orientation RAO, LAO RL, LL RL, LL None RAO, LAO
Spinal Fields: Number,
Orientation
1 − 3, PA 1, PA 1 − 3, PA 1 2, PA
Optimization "restrict to
disease site"
None stated Proton plans re-normalized for
comparison with Tomotherapy
plans
constraint to achieve uniform




(with respect to clinical target)
Not given 0.3 (Penumbra for
160 MeV protons)
Proximal: 0.2 Distal: 0.2 Lateral: 1
Smear: 0.3
0.5 (symmetric around CTV) Not given
Abbreviations in this table: right anterior oblique (RAO), left anterior oblique (LAO), right lateral (RL), left lateral (LL), posterior-to-anterior (PA).
*Newhauser et al. [39] used risk contributed by infield protons reported by Miralbell et al. and added risk contributed by stray neutrons based in phantom Monte
Carlo simulations of proton CSI fields (PA cranial field, PA upper spine field, and PA lower spine field).
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http://www.ro-journal.com/content/8/1/32that were used. In particular, Yuh et al. [10] reported on
the toxicity of 3 pediatric patients (3–4 years of age)
after CSI with protons, St Clair et al. [7] performed plan-
ning study of the comparative normal tissue sparing fol-
lowing conventional photon CSI, IMRT, and passively
scattered proton CSI for 1 patient (aged 43 months),
Yoon et al. [9] performed a dosimetric comparison of
CSI using tomotherapy vs. passively scattered protons
for 10 patients (mean age 7 years), Miralbell et al. [38]
compared risk of second cancers following proton, con-
ventional photon therapy, and IMRT in a 3 year old boy
for spinal irradiation (cranial fields not considered),
Newhauser et al. [39] compared the risk of second can-
cers from CSI using passively scattered proton, intensity
modulated proton, conventional photon, and IMRT in a
3 year old boy, Taddei et al. [8] considered the risk of
second cancers following CSI with passively scattered
protons in a male patient (age 10) versus a female pa-
tient (age 9). The proton treatment planning techniques
that were used in several of those studies (Table 4) indi-
cate that the methodology for passively scattered proton
CSI has varied considerably between studies. Specifically,
reported methodologies vary in almost all regards from
the orientation of the cranial fields to the definition of
the uncertainty margins. Of particular note is that there
is no specific mention of how the plans were optimized
for patient-specific anatomies, i.e., there is little agree-
ment for uncertainty margins used in the different stud-
ies, and there is no explanation of how uncertainty
margins were selected. Thus, there is a substantial po-
tential for differences in dosimetric results between stud-
ies, and this makes direct comparison of the dosimetric
results difficult. Nonetheless our dosimetric results are
in reasonably good agreement with previous investiga-
tions of proton CSI, including [7-10,32,38,39].
The problem of inter-institutional variations in plan-
ning for proton CSI, including variability in targetvolume definitions, specifically with respect to uncer-
tainty margins and dose constraints has been noted be-
fore [5]. Nonetheless, proton therapy is in evolution, and
as the evolution progresses, the need for standardized,
or at minimum documented and reproducible, planning
methods increases [5]. A standardized methodology is
clearly essential for robust dosimetric comparisons be-
tween centers and treatment modalities, and such com-
parisons are integral to progress in the area of randomized
trials. In the interim, there is potential for comparative in
silico studies, especially for populations (such as pediatric
populations) too small for randomized trials. However,
even in silico trials require a standardized planning meth-
odology because dose distributions across tumor and nor-
mal tissues are compared, and from these, conclusions are
drawn about the general effects of proton therapy relative
to photon therapy as in the studies of Yoon et al. [9] and
St. Clair et al. [7]). Nonetheless, progress is being made to-
ward actual randomized trials. For example, in a recent
work, Howell et al. [31] performed a dosimetric compari-
son using an actual patient population and the standar-
dized treatment planning methodology outlined here, and
they found that proton CSI improved normal tissue spar-
ing while also providing more homogeneous target cover-
age than photon CSI. Thus, the potential for similar
studies is growing, and with increased standardization, the
evidence from these studies is becoming increasingly
robust.Conclusions
This study described and evaluated a standardized
method for proton treatment planning for CSI. Overall,
the standardized planning methodology yielded consist-
ently high quality treatment plans and perhaps most im-
portantly, it did so for an anatomically diverse patient
population without creating outliers. Finally, the planning
Giebeler et al. Radiation Oncology 2013, 8:32 Page 15 of 16
http://www.ro-journal.com/content/8/1/32methodology described here can be used to provide guid-
ance to other proton centers as they implement CSI.
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